Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 200 of 375 entries
View as:

Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04099290 Org: User:
Start: 01/14/20 End: 02/02/26 Due: 02/02/27

Medically Tailored Meals for Kids

Phase: N/A Priority: Normal
NCT ID: NCT06814795 Org: User:
Start: 07/31/25 End: 01/31/26 Due: 01/31/27

Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study

Phase: N/A Priority: Normal
NCT ID: NCT04978350 Org: User:
Start: 10/01/21 End: 02/02/25 Due: 02/02/26

Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging

Phase: N/A Priority: Normal
NCT ID: NCT03761706 Org: User:
Start: 02/28/18 End: 02/01/25 Due: 02/01/26

Effectiveness of Central Oncology Navigation and the Use of an ORN

Phase: N/A Priority: Normal
NCT ID: NCT06618274 Org: User:
Start: 03/03/25 End: 07/01/31 Due: 07/01/32

Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04999085 Org: User:
Start: 12/01/21 End: 08/04/23 Due: 08/04/24

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

Phase: N/A Priority: Normal
NCT ID: NCT04176497 Org: User:
Start: 07/16/20 End: 02/07/28 Due: 02/07/29

Digital Breast Tomosynthesis Preference Study

Phase: N/A Priority: Normal
NCT ID: NCT00776126 Org: User:
Start: 10/31/08 End: 06/30/10 Due: 06/30/11

Streamlined Resin Y90 Radiation Segmentectomy for Small HCC

Phase: N/A Priority: Normal
NCT ID: NCT06618300 Org: User:
Start: 11/06/24 End: 12/31/27 Due: 12/31/28

RN-Led Palliative and Supportive Care Intervention

Phase: N/A Priority: Normal
NCT ID: NCT04570709 Org: User:
Start: 09/14/20 End: 06/06/24 Due: 06/06/25

Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT00767468 Org: User:
Start: 10/31/08 End: 11/30/10 Due: 11/30/11

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05498220 Org: User:
Start: 02/17/23 End: 08/31/28 Due: 08/31/29

Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey

Phase: N/A Priority: Normal
NCT ID: NCT05061095 Org: User:
Start: 03/21/22 End: 09/26/23 Due: 09/26/24

Impact of Financial Incentives

Phase: N/A Priority: Normal
NCT ID: NCT05744960 Org: User:
Start: 02/28/23 End: 08/31/26 Due: 08/31/27

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

Phase: N/A Priority: Normal
NCT ID: NCT05926024 Org: User:
Start: 01/06/23 End: 01/31/28 Due: 01/31/29

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00379509 Org: User:
Start: 04/30/06 End: 08/31/12 Due: 08/31/13

The Use of Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT02030353 Org: User:
Start: 01/31/14 End: 06/30/15 Due: 06/30/16

PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias

Phase: N/A Priority: Normal
NCT ID: NCT01169012 Org: User:
Start: 09/30/10 End: 01/31/13 Due: 01/31/14

HPV-Based Screen-and-Treat Demonstration Project in Lilongwe

Phase: N/A Priority: Normal
NCT ID: NCT04092257 Org: User:
Start: 06/24/20 End: 02/28/25 Due: 02/28/26

Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)

Phase: N/A Priority: Normal
NCT ID: NCT01316146 Org: User:
Start: 10/03/11 End: 05/04/22 Due: 05/04/23

Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00006110 Org: User:
Start: 12/31/98 End: 04/30/13 Due: 04/30/14

An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03765229 Org: User:
Start: 03/22/19 End: 07/31/23 Due: 07/31/24

Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02139774 Org: User:
Start: 10/31/13 End: 06/30/14 Due: 06/30/15

Single Subject Neratinib in Bladder Cancer (NRR)

Phase: N/A Priority: Normal
NCT ID: NCT01956253 Org: User:
Start: 07/31/13 End: 06/30/14 Due: 06/30/15

Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01751529 Org: User:
Start: 05/31/13 End: 11/30/15 Due: 11/30/16